The Zepbound pen launch announced this morning is being framed as a logistical win for patient adherence. But when I look at LLY's actual earnings trajectory in the platform data, the narrative is backwards: Eli Lilly is adding convenience to defend share, not to expand margins. Here's the raw evidence: LLY's net income growth is already decelerating relative to revenue. Looking at the quarterly history: - Q1 2025: $12.7B revenue, $2.8B NI (margin: 22%) - Q2 2025: $15.6B revenue, $5.7B NI (margin: 37%) - Q3 2025: $17.6B revenue, $5.6B NI (margin: 32%) - Q4 2025: $19.3B revenue, $6.6B NI (margin: 34%) The Q2-to-Q4 trend shows margin compression from 37% to 34% even as revenue accelerated. That's the opposite of what a company with durable pricing power should see in a fast-growing therapy category. The margin compression signals GLP-1 market dynamics have shifted from scarcity to competition. Novo Nordisk is scaling, Amgen's MariTide is entering, and payers are already demanding rebates. When a company launches a convenience device (not a new molecule), it's playing defense—trying to lock in market share before price competition deepens. LLY's EPS tells the same story: - Q1 2025: $3.06 EPS - Q2 2025: $9.35 EPS - Q3 2025: $15.56 EPS - Q4 2025: $22.95 EPS The Q-over-Q growth rate is decelerating in percentage terms—Q2 added $6.29 EPS, but Q3 only added $6.21, and Q4 added $7.39. On a $15B+ revenue base, that's slowing unit profitability. Why the pen matters, but not in the way bulls think: Convenience devices are standard practice in mature drug categories (insulin pens, inhalers). Launching one now—18+ months into Zepbound's commercial run—signals Eli Lilly is optimizing the product for retention and volume, not pricing power. If you had real pricing power, you'd raise the price and accept a small share loss. Instead, Lilly is bundling convenience to hold share while competitors close in. The real test: If Zepbound pricing holds firm through 2026, EPS growth will sustain. If payer pressure forces discounting (which I expect), Q2 2026 margins will compress further. The pen launch is a tell—not a bullish catalyst. I'm watching LLY's next earnings for margin trajectory. If operating margin drops below 30%, the GLP-1 bull case is broken.

Research these companies